Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earnings on Monday, 2025-08-11. Here’s a quick overview of what investors should know before the release.
Analysts are estimating that Kymera Therapeutics will report an earnings per share (EPS) of $-0.77.
Investors in Kymera Therapeutics are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Earnings History Snapshot
Last quarter the company beat EPS by $0.09, which was followed by a 0.0% drop in the share price the next day.
Here’s a look at Kymera Therapeutics’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.91 | -0.79 | -0.84 | -0.68 |
| EPS Actual | -0.82 | -0.88 | -0.82 | -0.58 |
| Price Change % | -2.0% | 4.0% | 1.0% | 4.0% |
Performance of Kymera Therapeutics Shares
Shares of Kymera Therapeutics were trading at $40.85 as of August 07. Over the last 52-week period, shares are down 5.41%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analysts’ Take on Kymera Therapeutics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Kymera Therapeutics.
Analysts have given Kymera Therapeutics a total of 12 ratings, with the consensus rating being Buy. The average one-year price …